Tarsus Pharmaceuticals, Inc.TARSNASDAQ
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank29
3Y CAGR+1.3%
5Y CAGR-34.1%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
+1.3%/yr
Annual compound
5Y CAGR
-34.1%/yr
Recent acceleration
Percentile
P29
Within normal range
vs 5Y Ago
0.1x
Contraction
Streak
2 yr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| 2025 | 80.07% |
| 2024 | 118.32% |
| 2023 | 141.83% |
| 2022 | 76.99% |
| 2021 | 220.43% |
| 2020 | 646.33% |
| 2019 | 137.05% |
| 2018 | 0.00% |